Cristin D. W. Kaspar

Cristin D. W. Kaspar

Auto-generated profile, based on publicly available information

Cristin D. W. Kaspar

Alnylam Pharmaceuticals, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
GLGuangbi Li
Guangbi Li
JKJason Kidd
Jason Kidd
CKCristin Kaspar
Cristin Kaspar
SDSara Dempsey
Sara Dempsey
OBOwais M. Bhat
Owais M. Bhat
PLPin-Lan Li
Pin-Lan Li

1 October 2017 in Journal of Pediatric Urology
Verified
Journal Article
Closed access
CKC.D.W. Kaspar
C.D.W. Kaspar
MLM. Lo
M. Lo
TBT.E. Bunchman
T.E. Bunchman
NXN. Xiao
N. Xiao

20 January 2020 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CKCristin D. W. Kaspar
Cristin D. W. Kaspar
IBIsidora Beach
Isidora Beach
JNJennifer Newlin
Jennifer Newlin
ISIndia Sisler
India Sisler
DFDaniel Feig
Daniel Feig
WSWally Smith
Wally Smith

12 August 2021 in Frontiers in Public Health
Verified
Journal Article
Open access
CKCristin D. W. Kaspar
Cristin D. W. Kaspar
JLJuan Lu
Juan Lu
Importance: High uric acid (UA) is hypothesized to worsen kidney and cardiovascular disease morbidity via activation of systemic inflammation. Clinical trials of UA modification report reduction of the inflammatory marker high sensitivity C-reactive protein (hs-CRP) as an outcome measure, but studies have not demonstrated that hyperuricemia independently increases hs-CRP when adjusted for important confounders such as body mass index (BMI), sex, and age.Objective: To identify clinical risk factors for elevated hs-CRP, including but not limited to hyperuricemia, through a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) 2015–2018.Results: In the final multivariate logistic regression model, the exposure with the strongest effect on the odds of elevated hs-CRP was BMI in the fourth quartile, OR = 13.1 (95% CI 6.25–27.42), followed by female sex (OR = 4.9, 95% CI 2.92–8.34), hyperuricemia (OR = 2.2, 95% CI 1.36–3.45), urine albumin creatinine ratio (ACR; OR = 1.5, 95% CI 1.09–2.18), poor overall health (OR = 1.4, 95% CI 1.18–1.58), and interactions between hyperuricemia and sex (OR = 1.4, 95% CI 1.05–1.83), and between BMI and sex (OR = 1.2, 95% CI 1.03–1.47). Notably, chronic kidney disease (CKD) and CKD surrogates were not associated with hs-CRP despite urine ACR maintaining a significant independent effect.Conclusions: In this national population-based study, we demonstrated that hyperuricemia significantly increases the odds of elevated hs-CRP, independent from BMI, female sex, urine ACR, and overall health status. Further study is recommended to better understand the sex difference in this association and the role of albuminuria, but not CKD, in systemic inflammation.

4 December 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
YFYaacov Frishberg
Yaacov Frishberg
JSJeffrey M. Saland
Jeffrey M. Saland
JLJohn C. Lieske
John C. Lieske
WDWeiming Du
Weiming Du
MCMartin Coenen
Martin Coenen
SHSally-Anne Hulton
Sally-Anne Hulton
Key Points: Primary hyperoxaluria type 1 is a genetic disorder associated with hepatic oxalate overproduction, kidney failure, and systemic oxalosis. Lumasiran treatment for up to 60 months was associated with sustained reductions in urinary and plasma oxalate and encouraging clinical outcomes. Lumasiran's safety profile was acceptable with mild injection site reactions being the most common adverse events. Background: Primary hyperoxaluria type 1 (PH1) is characterized by hepatic oxalate overproduction, kidney stones, and progressive kidney disease. Lumasiran is the first approved treatment for PH1. Methods: ILLUMINATE-A (NCT03681184) was a 60-month pivotal, phase 3, multinational clinical trial of lumasiran which consisted of a 6-month double-blind, placebo-controlled period (6M DB), followed by a treatment extension period of up to 54 months in which all patients received lumasiran. Eligible patients were aged ≥6 years with genetically confirmed PH1, eGFR ≥30 ml/min per 1.73 m 2 , and mean 24-hour urinary oxalate (UOx) excretion ≥0.70 mmol/24 h per 1.73 m 2 . Results: Of 39 patients enrolled, 24 of 26 randomized to lumasiran in the 6M DB (lumasiran/lumasiran group) and 13 of 13 randomized to placebo in the 6M DB (placebo/lumasiran group) completed the study. Sustained reductions in 24-hour UOx were observed in both treatment groups. At month 60 relative to study baseline, the mean (SEM) 24-hour UOx percentage reductions were 54 (6) and 54% (8%) in the lumasiran/lumasiran and placebo/lumasiran groups, respectively, and the mean (SEM) plasma oxalate concentrations had decreased by 35 (5) and 38% (7%). eGFR remained stable through the end of the study in both treatment groups. Kidney stone event rates during the study were 0.47 (95% confidence interval, 0.36 to 0.62) and 0.54 (0.37 to 0.78) per patient-year in the lumasiran/lumasiran group and placebo/lumasiran group, respectively. Medullary nephrocalcinosis grade improved at the end of the study in 21 of 28 (75%) patients with nephrocalcinosis at baseline and an end of study assessment. The safety profile of lumasiran was acceptable. Injection site reactions were the most common adverse events during lumasiran treatment. Most adverse events were mild or moderate in severity. Conclusions: Lumasiran treatment for up to 60 months in ILLUMINATE-A was associated with sustained reductions in UOx excretion and plasma oxalate concentration, encouraging clinical outcomes including stable eGFR in a population that would be expected to show eGFR decline, reduced kidney stone event rates, improved medullary nephrocalcinosis, and indications of improved health-related quality of life. Clinical Trial registry name and registration number: ClinicalTrials.gov NCT03681184. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2026_03_18_CJASNMar.21.3.31820.mp3

7 April 2023
Verified
Book Chapter
Closed access
PDF file
JLJeffrey Lebensburger
Jeffrey Lebensburger
CKCristin Kaspar
Cristin Kaspar